BRPI0924136B8 - composição farmacêutica sólida compreendendo amlodipina e losartan e método para a preparação da mesma - Google Patents

composição farmacêutica sólida compreendendo amlodipina e losartan e método para a preparação da mesma

Info

Publication number
BRPI0924136B8
BRPI0924136B8 BRPI0924136A BRPI0924136A BRPI0924136B8 BR PI0924136 B8 BRPI0924136 B8 BR PI0924136B8 BR PI0924136 A BRPI0924136 A BR PI0924136A BR PI0924136 A BRPI0924136 A BR PI0924136A BR PI0924136 B8 BRPI0924136 B8 BR PI0924136B8
Authority
BR
Brazil
Prior art keywords
amlodipine
losartan
pharmaceutical composition
solid pharmaceutical
same
Prior art date
Application number
BRPI0924136A
Other languages
English (en)
Inventor
Taek Yim Ho
Hyun Park Jae
Soo Kim Kyeong
Original Assignee
Hanmi Holdings Co Ltd
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42306870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0924136(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Holdings Co Ltd, Hanmi Science Co Ltd filed Critical Hanmi Holdings Co Ltd
Publication of BRPI0924136A2 publication Critical patent/BRPI0924136A2/pt
Publication of BRPI0924136A8 publication Critical patent/BRPI0924136A8/pt
Publication of BRPI0924136B1 publication Critical patent/BRPI0924136B1/pt
Publication of BRPI0924136B8 publication Critical patent/BRPI0924136B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Abstract

composição farmacêutica sólida compreendendo amlodipina e losartan e processo para a produção da mesma. a presente invenção se refere a uma composição farmacêutica sólida para evitar ou tratar desordens cardiovasculares compreendendo amlodipina ou um sal farmaceuticamente aceitável da mesma e losartan ou um sal farmaceuticamente aceitável do mesmo, que exibe elevados coeficientes de dissolução de amlodipina e losartan mesmo sob um condição de baixo ph e aprimorada estabilidade em armazenamento.
BRPI0924136A 2009-01-23 2009-02-13 composição farmacêutica sólida compreendendo amlodipina e losartan e método para a preparação da mesma BRPI0924136B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2009-0005840 2009-01-23
KR20090005840 2009-01-23
PCT/KR2009/000704 WO2010085014A1 (en) 2009-01-23 2009-02-13 Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same

Publications (4)

Publication Number Publication Date
BRPI0924136A2 BRPI0924136A2 (pt) 2017-06-13
BRPI0924136A8 BRPI0924136A8 (pt) 2017-10-03
BRPI0924136B1 BRPI0924136B1 (pt) 2019-10-15
BRPI0924136B8 true BRPI0924136B8 (pt) 2021-05-25

Family

ID=42306870

Family Applications (3)

Application Number Title Priority Date Filing Date
BRPI0924136A BRPI0924136B8 (pt) 2009-01-23 2009-02-13 composição farmacêutica sólida compreendendo amlodipina e losartan e método para a preparação da mesma
BRPI0924137A BRPI0924137A2 (pt) 2009-01-23 2009-06-05 composição farmacêutica sólida compreendendo amlodipina e losartan com melhor estabilidade
BRPI0924135A BRPI0924135A2 (pt) 2009-01-23 2009-12-28 composição farmacêutica sólida compreendendo anlodipino e losartan

Family Applications After (2)

Application Number Title Priority Date Filing Date
BRPI0924137A BRPI0924137A2 (pt) 2009-01-23 2009-06-05 composição farmacêutica sólida compreendendo amlodipina e losartan com melhor estabilidade
BRPI0924135A BRPI0924135A2 (pt) 2009-01-23 2009-12-28 composição farmacêutica sólida compreendendo anlodipino e losartan

Country Status (33)

Country Link
US (3) US9161933B2 (pt)
EP (3) EP2413931B1 (pt)
JP (3) JP5658172B2 (pt)
KR (2) KR101232296B1 (pt)
CN (4) CN102292085B (pt)
AR (3) AR070897A1 (pt)
AU (3) AU2009338267B2 (pt)
BR (3) BRPI0924136B8 (pt)
CA (3) CA2749903C (pt)
CL (1) CL2011001781A1 (pt)
CO (3) CO6361914A2 (pt)
CR (3) CR20110449A (pt)
DO (3) DOP2011000230A (pt)
EA (3) EA020103B1 (pt)
EC (1) ECSP11011253A (pt)
ES (3) ES2580777T3 (pt)
HK (1) HK1163539A1 (pt)
HN (2) HN2011002020A (pt)
IL (3) IL214147A (pt)
JO (2) JO2981B1 (pt)
MA (3) MA33056B1 (pt)
MX (3) MX349221B (pt)
MY (3) MY173823A (pt)
NI (3) NI201100143A (pt)
NZ (3) NZ594738A (pt)
PE (4) PE20100559A1 (pt)
SA (1) SA110310070B1 (pt)
SG (3) SG173044A1 (pt)
TW (3) TWI404534B (pt)
UA (3) UA102721C2 (pt)
UY (2) UY32388A (pt)
WO (3) WO2010085014A1 (pt)
ZA (3) ZA201106161B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009338267B2 (en) 2009-01-23 2014-09-18 Hanmi Science Co., Ltd. Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
JP6106359B2 (ja) * 2010-12-13 2017-03-29 第一三共ヘルスケア株式会社 ロキソプロフェンナトリウムとビタミンｂ１を含有する固形製剤
JP6041591B2 (ja) * 2011-09-13 2016-12-14 大日本住友製薬株式会社 イルベサルタンとアムロジピンまたはその塩を含有する安定化された医薬組成物
KR101907881B1 (ko) * 2011-12-30 2018-12-11 한미약품 주식회사 로자탄, 암로디핀 및 히드로클로로티아자이드를 포함하는 고정 용량 조합 제형
CN102600146B (zh) * 2012-04-11 2014-10-08 兆科药业（合肥）有限公司 一种盐酸乐卡地平和氯沙坦钾复方制剂及其制备方法
KR101392364B1 (ko) * 2012-04-17 2014-05-07 한국유나이티드제약 주식회사 안정성이 향상된 암로디핀 및 로잘탄을 함유하는 복합제 조성물
JP6160263B2 (ja) * 2012-06-07 2017-07-12 大正製薬株式会社 ロキソプロフェン含有医薬組成物
KR101506148B1 (ko) * 2013-09-24 2015-03-26 대봉엘에스 주식회사 직접 타정할 수 있는 암로디핀 및 로사르탄을 포함하는 약제학적 조성물, 및 이에 의해 제조된 정제
WO2015072700A1 (en) * 2013-11-15 2015-05-21 Hanmi Pharm. Co., Ltd. Composite formulation comprising tadalafil and amlodipine
KR20150056443A (ko) * 2013-11-15 2015-05-26 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합제제
KR101910901B1 (ko) * 2013-11-29 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
KR102369607B1 (ko) 2014-09-30 2022-03-03 한미약품 주식회사 암로디핀 및 로잘탄을 포함하는 고형 약제학적 조성물
CN104610130A (zh) * 2015-01-22 2015-05-13 华东理工常熟研究院有限公司 氨氯地平-棕榈酸离子液体及其制备方法和用途
KR101914930B1 (ko) 2015-03-31 2018-11-05 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합 제제
KR20170003459A (ko) * 2015-06-30 2017-01-09 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
KR101750689B1 (ko) * 2015-09-15 2017-06-26 주식회사 종근당 약제학적 복합제제
CN107260735A (zh) * 2017-07-25 2017-10-20 合肥华方医药科技有限公司 生物利用度提高的二氢吡啶类药物组合物
CN107308158A (zh) * 2017-07-28 2017-11-03 合肥华方医药科技有限公司 一种提高非洛地平生物利用度的药物组合物
CN107308159A (zh) * 2017-07-28 2017-11-03 合肥华方医药科技有限公司 一种提高伊拉地平生物利用度药物组合物
JP7166754B2 (ja) * 2017-11-22 2022-11-08 沢井製薬株式会社 ダサチニブ無水物含有製剤
CN108542891A (zh) * 2018-06-07 2018-09-18 董贵雨 一种含有替格瑞洛的固体药物组合物
JP2020090471A (ja) * 2018-12-07 2020-06-11 ニプロ株式会社 アジルサルタン及びアムロジピンを含有する医薬組成物及びその製造方法
KR102233986B1 (ko) * 2019-06-25 2021-03-30 경남과학기술대학교 산학협력단 라푸티딘 및 이르소글라딘을 함유하는 고형 약제학적 조성물 및 이의 제조방법
KR20210074428A (ko) 2019-12-11 2021-06-22 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제
CN115666564A (zh) 2020-06-09 2023-01-31 韩美药品株式会社 在单层片剂中包括氨氯地平、氯沙坦和氯噻酮的预防或治疗心血管系统疾病的药学上组合制剂
CN112274490B (zh) * 2020-11-19 2022-11-22 四川尚锐生物医药有限公司 一种氨氯地平氯沙坦钾复方组合物的制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA2179067A1 (en) 1993-12-23 1995-06-29 Gordon Creston Campbell, Jr. Polymorphs of losartan and the process for the preparation of form ii of losartan
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
CA2383252A1 (en) * 1999-08-24 2001-03-01 Medicure International Inc. Treatment of cardiovascular related pathologies
EP1106210A3 (en) * 1999-12-07 2003-12-03 Pfizer Products Inc. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
WO2002002081A1 (en) * 2000-07-05 2002-01-10 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and methods of using same
CA2420844A1 (en) * 2000-08-30 2003-02-28 Sankyo Company, Limited Medicinal compositions for preventing or treating heart failure
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
KR100452491B1 (ko) * 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
WO2003035046A2 (en) 2001-10-18 2003-05-01 Novartis Ag Salts formed of an at1-receptor antagonist and a cardiovascular agent
MXPA04004657A (es) 2001-11-14 2004-08-13 Teva Pharma Formas amorfas y cristalinas de potasio de losartan y proceso para su preparacion.
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US7157100B2 (en) 2002-06-04 2007-01-02 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
MXPA05007876A (es) 2003-01-27 2005-09-21 Hanmi Pharm Ind Co Ltd Camsilato de amlodipino amorfo, estable, proceso para preparar el mismo y composicion para la administracion oral del mismo.
US7591797B2 (en) * 2003-07-18 2009-09-22 Pneu Medex Inc. Fluid operated actuators and pneumatic unloading orthoses
UA87983C2 (ru) 2003-07-31 2009-09-10 Никокс С.А. Производные блокиратора рецептора ангиотензина ii
US20050209288A1 (en) 2004-01-12 2005-09-22 Grogan Donna R Compositions comprising (S)-amlodipine malate and an angiotensin receptor blocker and methods of their use
MX366895B (es) * 2004-11-05 2019-07-30 Boehringer Ingelheim Int Gmbh Star Comprimido bicapa que comprende telmisartán y amlodipina.
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
WO2007001065A2 (en) 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Method for the preparation of a wet granulated drug product
TWI388345B (zh) 2005-06-27 2013-03-11 Sankyo Co 用於高血壓之預防或治療之包含血管緊張素ⅱ受體拮抗劑及鈣通道阻斷劑之固體劑型
AU2006307470A1 (en) * 2005-10-27 2007-05-03 Lupin Limited Pharmaceutical formulation of losartan
BRPI0618371A2 (pt) 2005-11-08 2011-08-30 Novartis Ag combinação de compostos orgánicos
AR058605A1 (es) * 2005-12-22 2008-02-13 Takeda Pharmaceutical Preparacion solida
KR100742432B1 (ko) * 2005-12-27 2007-07-24 한미약품 주식회사 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법
KR100913791B1 (ko) 2006-07-21 2009-08-26 한미약품 주식회사 (ｓ)-(-)-암로디핀 캠실레이트 또는 이의 수화물 및 이를함유하는 약학적 조성물
US20080051438A1 (en) 2006-08-11 2008-02-28 Shinobu Nagahama Preventive/Therapeutic Compositions Useful for Treating Cardiovascular Diseases
WO2008023958A1 (en) 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
US20080241240A1 (en) 2006-08-24 2008-10-02 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
WO2008023869A1 (en) 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
KR101247583B1 (ko) 2006-12-08 2013-03-26 한미사이언스 주식회사 암로디핀 또는 이의 약제학적 허용가능한 염, 및 로자탄또는 이의 약제학적 허용가능한 염을 함유하는 약제학적조성물
AU2009338267B2 (en) 2009-01-23 2014-09-18 Hanmi Science Co., Ltd. Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same

Also Published As

Publication number Publication date
MX2011006008A (es) 2011-06-28
EP2391365B1 (en) 2014-11-26
ES2505116T3 (es) 2014-10-09
AU2009338267A2 (en) 2011-09-29
JP2012515768A (ja) 2012-07-12
AU2009338280B2 (en) 2014-05-01
UY32388A (es) 2010-02-26
US8673945B2 (en) 2014-03-18
JP5466716B2 (ja) 2014-04-09
MY151550A (en) 2014-06-13
EA020103B1 (ru) 2014-08-29
UA105203C2 (ru) 2014-04-25
HN2011002020A (es) 2014-02-03
AU2009338267A1 (en) 2011-09-15
CR20110450A (es) 2011-11-10
CN105998017A (zh) 2016-10-12
CN102292084A (zh) 2011-12-21
IL214146A0 (en) 2011-08-31
JO3328B1 (ar) 2019-03-13
BRPI0924136A2 (pt) 2017-06-13
MX349221B (es) 2017-07-19
NZ594738A (en) 2013-11-29
UY32389A (es) 2010-02-26
EP2391348B1 (en) 2014-08-27
AU2009338251A1 (en) 2011-09-15
IL214147A0 (en) 2011-08-31
CA2749903A1 (en) 2010-07-29
UA102721C2 (uk) 2013-08-12
US20110251245A1 (en) 2011-10-13
US9161933B2 (en) 2015-10-20
WO2010085047A3 (en) 2010-11-04
ZA201106160B (en) 2012-10-31
CO6361905A2 (es) 2012-01-20
AR075027A1 (es) 2011-03-02
EP2391348A4 (en) 2012-07-25
CN102292085B (zh) 2017-01-18
CL2011001781A1 (es) 2012-03-23
WO2010085014A1 (en) 2010-07-29
EA019471B1 (ru) 2014-03-31
UA102720C2 (ru) 2013-08-12
JO2981B1 (ar) 2016-09-05
TW201028151A (en) 2010-08-01
MA33056B1 (fr) 2012-02-01
CN102292070A (zh) 2011-12-21
CA2749903C (en) 2016-09-06
ZA201106162B (en) 2012-10-31
CO6361914A2 (es) 2012-01-20
MA33057B1 (fr) 2012-02-01
NI201100145A (es) 2012-08-17
AU2009338267B2 (en) 2014-09-18
MX2011006061A (es) 2011-06-24
MX345956B (es) 2017-02-28
NI201100144A (es) 2012-11-06
HN2011002022A (es) 2014-02-03
EP2413931B1 (en) 2016-06-01
TW201031404A (en) 2010-09-01
NI201100143A (es) 2012-08-17
SG173046A1 (en) 2011-08-29
AU2009338251B2 (en) 2014-03-13
SG173045A1 (en) 2011-08-29
MX2011006009A (es) 2011-06-28
CO6361915A2 (es) 2012-01-20
TWI395583B (zh) 2013-05-11
SA110310070B1 (ar) 2014-09-02
EA201170958A1 (ru) 2012-01-30
NZ594740A (en) 2013-11-29
AR075028A1 (es) 2011-03-02
BRPI0924136A8 (pt) 2017-10-03
US8673944B2 (en) 2014-03-18
US20110245302A1 (en) 2011-10-06
MX345868B (es) 2017-02-21
WO2010085027A1 (en) 2010-07-29
ES2580777T3 (es) 2016-08-26
PE20100559A1 (es) 2010-09-12
MY150974A (en) 2014-03-31
BRPI0924136B1 (pt) 2019-10-15
AU2009338280A1 (en) 2011-09-15
EP2413931A1 (en) 2012-02-08
CA2749957C (en) 2016-07-26
DOP2011000229A (es) 2011-10-15
JP5660544B2 (ja) 2015-01-28
EP2391348A1 (en) 2011-12-07
EA201170960A1 (ru) 2012-01-30
EP2391365A2 (en) 2011-12-07
WO2010085047A2 (en) 2010-07-29
IL214145A0 (en) 2011-08-31
DOP2011000231A (es) 2011-10-15
MA33058B1 (fr) 2012-02-01
IL214147A (en) 2016-08-31
CA2749955A1 (en) 2010-07-29
EP2413931A4 (en) 2012-08-08
CA2749957A1 (en) 2010-07-29
KR101160151B1 (ko) 2012-06-27
ZA201106161B (en) 2012-10-31
HK1163539A1 (en) 2012-09-14
BRPI0924135A2 (pt) 2016-02-10
DOP2011000230A (es) 2011-10-15
CR20110449A (es) 2011-11-10
ES2526606T3 (es) 2015-01-13
TWI404534B (zh) 2013-08-11
PE20100739A1 (es) 2010-11-19
KR20100086921A (ko) 2010-08-02
MY173823A (en) 2020-02-24
CN102292084B (zh) 2014-01-29
US20110245301A1 (en) 2011-10-06
EA021763B1 (ru) 2015-08-31
CA2749955C (en) 2016-07-26
CR20110448A (es) 2011-11-10
CN102292085A (zh) 2011-12-21
AR070897A1 (es) 2010-05-12
KR20100086913A (ko) 2010-08-02
SG173044A1 (en) 2011-08-29
ES2580777T8 (es) 2016-09-22
EA201170959A1 (ru) 2011-12-30
EP2391365A4 (en) 2012-07-25
PE20120428A1 (es) 2012-05-17
KR101232296B1 (ko) 2013-02-13
JP2012515767A (ja) 2012-07-12
PE20140978A1 (es) 2014-08-16
JP2012515770A (ja) 2012-07-12
JP5658172B2 (ja) 2015-01-21
BRPI0924137A2 (pt) 2019-09-24
NZ594739A (en) 2013-11-29
ECSP11011253A (es) 2011-09-30

Similar Documents

Publication Publication Date Title
BRPI0924136B8 (pt) composição farmacêutica sólida compreendendo amlodipina e losartan e método para a preparação da mesma
BRPI0909614A2 (pt) "composto, composição farmacêutica, método de tratamento de um transtorno hiperproliferativo em um mamífero, processo para a preparação de uma composição farmacêutica, método para a inibição ou modulação da atividade de quinase de lipídio em um mamífero, kit para o tratamento de condição mediada por pi3k e método de preparação de um composto da fórmula
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
IN2014KN00948A (pt)
BRPI0906786A2 (pt) Composto, processo para a preparação de um composto, uso de um composto, método para o tratamento de uma doença ou condição, composição farmacêutica, processo para a preparação de uma composição farmacêutica, produto, e, kit.
BR112012028530A2 (pt) composto, composição farmacêutica e seu processo de preparação e método para o tratamento de uma doença ou transtorno
BRPI0922566A2 (pt) polimorfo cristalino, composição farmacêutica, composto, e, métodos para preparar um composto, e para tratar uma doença.
CL2013002729A1 (es) Elemento de filtro para un articulo para fumar, que incluye fibras formadas a partir de una composicion que comprende una mezcla de un polilactido (pla), un polimero soluble en agua, y un agente compatibilizador reactivo; y metodo para preparar un elemento de filtro.
BR112012005319A2 (pt) método para produzir uma resina sequestrante de oxigênio, composição e método para produzir um artigo
BRPI1010970A2 (pt) solução farmacêutica, processo para preparar uma solução farmacêutica e método para tratamento
BRPI0909198A2 (pt) composto antifolato, composto, método para preparar um composto antifolato, composição farmacêutica, método para tratar
BR112012003462A2 (pt) "composto, composição farmacêutica, e, método para tratar um paciente tendo uma condição mediada pela proteína quinase."
BR112012003464A2 (pt) composto, composição farmacêutica, usos de uma composição farmacêutica e de um composto, e, método para tratar uma doença ou um distúrbio."
BRPI0716069A2 (pt) composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio
CO6362012A2 (es) Clohidarto de nalmefeno dihidratado
ECSP11011048A (es) Inhibidores de cinasa akt y p70 s6
EA201001524A1 (ru) Ингибиторы дезацетилазы в, основанные на гидроксамате
WO2010110545A2 (ko) 신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물
NO20074843L (no) Nye salter av 6-heterocyklylsubstituerte heksahydrofenantridinderivater
BRPI0817721A2 (pt) Composto, composição farmacêutica, método de tratamento, e, processo para preparação de um composto
BRPI0911709A2 (pt) composto, processo para a produção de um composto, composição farmacêutica e método de tratar uma doença mediada a ciclofilina em um mamífero
BR112012002500A2 (pt) Processo para o preparo de derivados de ácido 1- (2-halobifenil-4-yl) - ciclopropanocarboxílico
BRPI0913343A2 (pt) Método para produção do composto 2,4,6-tri(hidroxifenil)-1,3,5-triazina
BRPI1008214A2 (pt) "composto de pirazina da fórmula i, composto da fórmula i, processo para preparar o composto da fórmula i, composição e método para controlar uma vegetação indesejável"
BRPI0817445A2 (pt) composto, composição farmacêutica, método de tratamento, e, processo para preparar um composto

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: HANMI SCIENCE CO., LTD. (KR)

B25G Requested change of headquarter approved

Owner name: HANMI SCIENCE CO., LTD. (KR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/10/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/10/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/02/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2658 DE 14-12-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.